^
    1d
    Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement (clinicaltrials.gov)
    P3, N=200, Active, not recruiting, Rush University Medical Center | N=100 --> 200
    Enrollment change • Head-to-Head
    |
    rifampicin
    4d
    Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement (clinicaltrials.gov)
    P3, N=100, Active, not recruiting, Rush University Medical Center | Suspended --> Active, not recruiting | Trial primary completion date: Dec 2025 --> May 2026
    Enrollment closed • Trial primary completion date • Head-to-Head
    |
    rifampicin
    7d
    A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets (clinicaltrials.gov)
    P1, N=40, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Completed
    Trial completion
    |
    itraconazole • rifampicin • rovadicitinib (TQ05105)
    9d
    QUANTUM: A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis (clinicaltrials.gov)
    P3, N=532, Recruiting, Otsuka Pharmaceutical Development & Commercialization, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    rifampicin
    11d
    INSPIRE-BLMZ: Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort (clinicaltrials.gov)
    P3, N=120, Not yet recruiting, Beijing Chest Hospital
    New P3 trial
    |
    rifampicin
    17d
    Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin (clinicaltrials.gov)
    P1, N=20, Recruiting, Brigham and Women's Hospital | Trial completion date: Mar 2025 --> Dec 2026 | Trial primary completion date: Mar 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    rifampicin
    23d
    A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants (clinicaltrials.gov)
    P1, N=63, Completed, Incyte Corporation | Recruiting --> Completed
    Trial completion
    |
    itraconazole • rifampicin
    28d
    A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, Celgene
    New P1 trial
    |
    itraconazole • rifampicin
    2ms
    A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Rifampin on INCB123667 When Administered Orally to Healthy Adult Participants (clinicaltrials.gov)
    P1, N=51, Recruiting, Incyte Corporation | Completed --> Recruiting | N=15 --> 51 | Trial completion date: May 2025 --> Mar 2026 | Trial primary completion date: May 2025 --> Feb 2026
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    itraconazole • rifampicin
    2ms
    Repurposing antibiotics: A dual-action approach against bacteria-induced cancer. (PubMed, Cancer Pathog Ther)
    Antibiotics such as doxycycline, rifampicin, and azithromycin demonstrate anticancer properties by inhibiting angiogenesis, inducing apoptosis, and regulating key pathways including the interleukin (IL)-6 signaling pathway and autophagy-related pathways. By elucidating the pivotal role of biofilms in persistent infections and highlighting untapped therapeutic opportunities in antibiotic repurposing, this review underscores a transformative approach to cancer treatment. This article explores the potential of repurposing antibiotic drugs for cancer treatment and highlights the prospects of drug repurposing strategies.
    Review • Journal
    |
    IL6 (Interleukin 6)
    |
    rifampicin
    2ms
    Cyp3a4-Mediated in vitro Metabolism and in vivo Disposition of Lorlatinib in Rats. (PubMed, Drug Des Devel Ther)
    Pharmacokinetic (PK) studies were performed in Sprague-Dawley (SD) rats following oral and intravenous dosing, including coadministration with CYP3A4 inhibitors (voriconazole, itraconazole) and inducers (rifampicin, carbamazepine). Significant interspecies differences between HLM and RLM emphasize the need for caution when translating preclinical findings. Coadministration with CYP3A4 modulators markedly altered systemic exposure, while effective brain penetration supports its therapeutic role in central nervous system (CNS) metastases.
    Preclinical • Journal
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    Lorbrena (lorlatinib) • itraconazole • rifampicin
    2ms
    A Multicenter, Open-label, Randomized, Active-controlled Clinical Study to Compare the Efficacy and Safety of Different Combination Regimens of JDB0131 Benzenesulfonate Tablets with Delamanid in Patients with Rifampin-resistant Tuberculosis (JD-RISE) (ChiCTR2500108732)
    P2, N=60, Not yet recruiting, Beijing Chest Hospital, Capital Medical University; WestVac Biopharma Co., Ltd.
    New P2 trial
    |
    rifampicin